Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Long-Term Investments: 2022-2024

Historic Long-Term Investments for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $12.5 million.

  • Corvus Pharmaceuticals' Long-Term Investments fell 24.08% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year decrease of 24.08%. This contributed to the annual value of $12.5 million for FY2024, which is 22.22% down from last year.
  • Corvus Pharmaceuticals' Long-Term Investments amounted to $12.5 million in FY2024, which was down 22.22% from $16.1 million recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Long-Term Investments ranged from a high of $21.9 million in FY2022 and a low of $12.5 million during FY2024.
  • For the 3-year period, Corvus Pharmaceuticals' Long-Term Investments averaged around $16.8 million, with its median value being $16.1 million (2023).
  • Data for Corvus Pharmaceuticals' Long-Term Investments shows a maximum YoY declined of 26.30% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Corvus Pharmaceuticals' Long-Term Investments stood at $21.9 million in 2022, then declined by 26.30% to $16.1 million in 2023, then dropped by 22.22% to $12.5 million in 2024.